Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Medicinteknik |
US sales started
"During the second quarter, we reached a significant milestone by recording our first IRRAflow revenue in the United States (US). The US is the world's largest market for neurosurgical procedures, and with the ongoing CE Mark recertification process, we have focused much of our team's resources toward supporting a successful early market introduction in the US."
Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS
- Net revenue totaled SEK 1.1 million (0.1)
- Operating loss (EBIT) amounted to SEK -40.7 million (-32.1)
- Loss after tax totaled SEK -40.2 million (-29.1)
- Earnings per share before and after dilution amounted to SEK -1.55 (-1.23)
- Net revenue totaled SEK 1.1 million (6.0)
- Operating loss (EBIT) amounted to SEK -79.8 million (-53.2)
- Loss after tax totaled SEK -78.9 million (-47.0)
- Earnings per share before and after dilution amounted to SEK -3.15 (-1.99)
- Acquisition of complementary medical device technology
- Position strengthened through acquisition of proprietary assets
- IRRAflow wins regulatory approval in Israel and Costa Rica
- Update on CE Mark re-certification of IRRAflow
- New Board member
- Changes in management group
- Raising capital through directed share issue
In May, the company completed a directed share issue and net proceeds to the company amounted to SEK 97.3 million. The subscribers in the issue were a number of Swedish and international institutional investors.
Important events after the end of the quarter- No important events have taken place after the end of the quarter.
About IRRAS
IRRAS AB (Nasdaq First North Premier: IRRAS) is a global healthcare company focused on delivering innovative medical technologies to our customers and their patients. IRRAS designs, develops and commercializes products that improve patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methods in neurocritical care. IRRAS markets and sells its products to hospitals worldwide through its direct sales organizations in the U.S. and select European countries and a network of distribution partners in other markets.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier. Redeye AB is certified adviser of the company with email certifiedadviser@redeye.se orphone 08-121 576 90.
For more information, please contact:
USA
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
info@irras.com
Europa
Sabina Berlin
CFO
+46 73 951 95 02
sabina.berlin@irras.com
This document is considered information that IRRAS is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person above, on August 29, 2019 at 8:00 a.m. (CET).